Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
Harrison CN, Mesa R, Talpaz M, Gupta V, Gerds AT, Perkins A, Goh YT, Fox ML, McLornan D, Palmer J, Foltz L, Vannucchi A, Koschmieder S, Passamonti F, Lee SE, Ellis C, Strouse B, Gonzalez Carreras FJ, Oh ST. Harrison CN, et al. Among authors: gerds at. Clin Lymphoma Myeloma Leuk. 2024 Oct 16:S2152-2650(24)02359-0. doi: 10.1016/j.clml.2024.10.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39516087 Free article.
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data.
Gerds AT, Tkacz J, Moore-Schiltz L, Schinkel J, Phiri K, Liu T, Gorsh B. Gerds AT, et al. J Manag Care Spec Pharm. 2024 Dec;30(12):1395-1404. doi: 10.18553/jmcp.2024.24050. Epub 2024 Oct 3. J Manag Care Spec Pharm. 2024. PMID: 39360964 Free PMC article.
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, Yacoub A, Sirhan S, Ellis C, Patel B, Strouse B, Platzbecker U. Harrison CN, et al. Among authors: gerds at. Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11. Adv Ther. 2024. PMID: 38990433 Free PMC article. Clinical Trial.
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.
Gotlib J, Gerds AT, Abdelmessieh P, Ali H, Castells M, Dunbar A, Fein Revell R, George TI, Green S, Gundabolu K, Hexner E, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, Manchanda N, Masarova L, May J, McMahon B, Mohan SR, Nadiminti KV, Oh S, Palmer J, Patel A, Patel AA, Podoltsev N, Rein L, Salit R, Talpaz M, Wadleigh M, Wall S, Bergman MA, Hochstetler C. Gotlib J, et al. Among authors: gerds at. J Natl Compr Canc Netw. 2024 Jun;22(2 D):e240030. doi: 10.6004/jnccn.2024.0030. J Natl Compr Canc Netw. 2024. PMID: 38862005
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, Bose P, Kremyanskaya M, Mead AJ, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Gerds AT, et al. Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939. Blood Adv. 2024. PMID: 38820422 Free PMC article.
Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Vachhani P, et al. Among authors: gerds at. Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38380373 Free PMC article. Review.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Yacoub A, et al. Among authors: gerds at. Blood Adv. 2024 Mar 26;8(6):1515-1528. doi: 10.1182/bloodadvances.2023011620. Blood Adv. 2024. PMID: 38290135 Free PMC article. Clinical Trial.
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. Metheny LL, et al. Among authors: gerds at. Blood Adv. 2024 Mar 26;8(6):1384-1391. doi: 10.1182/bloodadvances.2023011514. Blood Adv. 2024. PMID: 38170741 Free PMC article.
135 results